. A) For functional in-vitro studies, the specific mTOR inhibitor Torin-1 was applied. Western blot anaylsis revealed that Torin-1 decreased the TNF induced activation of P70S6K and AKT in a dose dependent manner in RA-FLS, indicating that the phosphorylation of these proteins by TNF depends on mTOR. B) TNF is well known to increase FLS proliferation. The addition of Torin-1 (250 nM), however, completely overruled TNF-induced FLS proliferation in a thymidine incooperation assay. C) Importantly, Torin-1 (250 nM) alone or in combination with TNF (10 ng/ml), had no effect on cell viability. Cell viability was assessed by Annexin V/7-AAD stainings and flow cytometry. D) Torin also prevented the TNF induced lining layer hyperplasia in a 3-D in-vitro synovial organ culture system. To further determine the effect of mTOR activation for the TNF driven mesenchymal inflammatory response, RA-FLS (n=5) were exposed to TNF in the presence or the absence of Torin. TNF-stimulation resulted in the upregualted expression of 587 genes (FDR<0,01). Surprisingly, 141 of those transcripts were further upregulated, when FLS were treated with TNF in the presence of Torin. Importantly, this group contained transcripts that are well known to be involved in RA pathogenesis, including IL-6, IL-8, CCL20 or MMP1. Interestingly, these transcripts were found to be specifically enriched for genes containing NFkappaB regulatory motifs in their promotors. B) Validation of selected candidates by RT-PCR. C) Western blot analysis revealed that inhibition of mTOR by Torin attenuated the re-synthesis of the NFkappaB inhibitor IKBα in TNF treated FLS. 
